Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
21.01
+0.36 (1.74%)
At close: Nov 18, 2026, 4:00 PM EST
21.49
+0.48 (2.28%)
After-hours: Nov 18, 2026, 7:45 PM EST
Beam Therapeutics Revenue
Beam Therapeutics had revenue of $307.00K in the quarter ending September 30, 2026, a decrease of -96.83%. This brings the company's total for the last twelve months to $146.64M, up 163.27% year-over-year. In the year 2025, Beam Therapeutics had annual revenue of $139.74M with 120.01% growth. That makes Beam Therapeutics the 19,816th largest company in the world by revenue and 3,054th in the United States.
Revenue (ttm)
$146.64M
Revenue Growth
+163.27%
P/S Ratio
14.28
Revenue / Employee
$263,275
Employees
557
Market Cap
2.09B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 139.74M | 76.23M | 120.01% |
| Dec 31, 2024 | 63.52M | -314.19M | -83.18% |
| Dec 31, 2023 | 377.71M | 316.79M | 520.01% |
| Dec 31, 2022 | 60.92M | 9.08M | 17.51% |
| Dec 31, 2021 | 51.84M | 51.82M | 215,916.67% |
| Dec 31, 2020 | 24.00K | 6.00K | 33.33% |
| Dec 31, 2019 | 18.00K | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Lakefront Biotherapeutics NV | 1.13B |
| Harmony Biosciences Holdings | 989.36M |
| Aurinia Pharmaceuticals | 321.74M |
| Maravai LifeSciences Holdings | 213.00M |
| Septerna | 96.27M |
| Immunome | 4.02M |
| Celldex Therapeutics | 158.00K |
BEAM News
- 15 hours ago - Beam Therapeutics Transcript: Jefferies Global Healthcare Conference - Transcripts
- 1 day ago - Beam Therapeutics Transcript: UBS Global Biopharma Conference 2026 - Transcripts
- 8 days ago - Beam Therapeutics price target raised to $33 from $30 at Wedbush - TheFly
- 8 days ago - Beam Therapeutics reports BEACON trial achieves primary efficacy endpoint - TheFly
- 8 days ago - Beam Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 8 days ago - Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease - GlobeNewsWire
- 13 days ago - Beam Therapeutics price target lowered to $51 from $55 at Guggenheim - TheFly
- 14 days ago - Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire